Gynecologic Cancer
Opinion
Disparity in endometrial cancer outcomes: What can we do?
Black women report symptoms less, have more delays in diagnosis, and experience more frequent deviations from guideline-directed diagnostics.
Opinion
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
They recommend using screening tools focusing on family history that primary care physicians can utilize to determine who should be referred for...
News
Is it time to expand the use of PARP inhibitors?
Dr. Alan P. Lyss breaks down new findings presented at the European Society of Medical Oncology Congress on the expanded use of PARP inhibitors in...
Conference Coverage
Veliparib improves PFS in high-grade serous epithelial ovarian cancer
BARCELONA – Adding veliparib to frontline CT and maintenance significantly extended PFS in women with high-grade...
Opinion
The law of unintended consequences
Dr. Alan P. Lyss examines the impact of women’s health clinic closures and excessive radiation doses in some lung cancer screening programs.
From the Journals
Pilot program benefits gynecologic cancer patients with malignant bowel obstruction
Among patients with advanced gynecologic cancer and malignant bowel obstruction, hospital length of stay decreased after the implementation of a...
Conference Coverage
PRIMA study: Niraparib maintenance improves PFS in advanced OC
BARCELONA – Niraparib improves PFS when given after first-line chemotherapy for advanced ovarian cancer, according...
Conference Coverage
PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer
BARCELONA – Benefit was particularly pronounced in patients with a tumor BRCA mutation and those with homologous recombination deficiency (HRD)–...
Conference Coverage
BAROCCO study: Cediranib-olaparib combination shows promise in PROC
BARCELONA –
Conference Coverage
Closure of women’s health clinics may negatively impact cervical cancer outcomes
Mortality risk among women with cervical cancer was 36% higher in states that had a decreased number of women’s clinics.
News
FDA approves pembrolizumab/lenvatinib combo for advanced endometrial carcinoma
The approval is based on positive results from the KEYNOTE-146 trial.